M
Mary E. Griffith
Researcher at Johns Hopkins University School of Medicine
Publications - 5
Citations - 506
Mary E. Griffith is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Cancer & Gemcitabine. The author has an hindex of 4, co-authored 5 publications receiving 405 citations. Previous affiliations of Mary E. Griffith include Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma
Joseph M. Herman,Daniel T. Chang,Karyn A. Goodman,Avani S. Dholakia,Siva P. Raman,Amy Hacker-Prietz,Christine A. Iacobuzio-Donahue,Mary E. Griffith,Timothy M. Pawlik,Jonathan S. Pai,Eileen M. O'Reilly,George A. Fisher,Aaron T. Wild,Lauren M. Rosati,Lei Zheng,Christopher L. Wolfgang,Daniel A. Laheru,Laurie Ann Columbo,Elizabeth A. Sugar,Albert C. Koong +19 more
TL;DR: This phase 2 multi‐institutional study was designed to determine whether gemcitabine with fractionated stereotactic body radiotherapy (SBRT) results in acceptable late grade 2 to 4 gastrointestinal toxicity when compared with a prior trial of GEM with single‐fraction SBRT in patients with locally advanced pancreatic cancer (LAPC).
Journal ArticleDOI
Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy
Avani S. Dholakia,Muhammad A. Chaudhry,Jeffrey P. Leal,Daniel T. Chang,Siva P. Raman,Amy Hacker-Prietz,Zheng Su,Jonathan S. Pai,Katharine E. Oteiza,Mary E. Griffith,Richard L. Wahl,Erik Tryggestad,Timothy M. Pawlik,Daniel A. Laheru,Christopher L. Wolfgang,Albert C. Koong,Joseph M. Herman +16 more
TL;DR: Pre-SBRT MTV and TLG are potential predictive factors for overall survival in patients with LAPC and may assist in tailoring therapy.
Journal ArticleDOI
Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer
Avani D. Rao,Elizabeth A. Sugar,Daniel T. Chang,Karyn A. Goodman,Amy Hacker-Prietz,Lauren M. Rosati,Laurie Ann Columbo,Eileen M. O'Reilly,George A. Fisher,Lei Zheng,Jonathan S. Pai,Mary E. Griffith,Daniel A. Laheru,Christine A. Iacobuzio-Donahue,Christopher L. Wolfgang,Albert C. Koong,Joseph M. Herman +16 more
TL;DR: In this exploratory analysis, patients experience clinically relevant short-term improvements in pancreatic cancer-specific symptoms and SBRT can be easily integrated with other systemic therapies and may be a potential standard of care option in patients with LAPC.
Journal ArticleDOI
A Phase 2 Multicenter Study to Evaluate Gemcitabine and Fractionated Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Adenocarcinoma
Avani S. Dholakia,Daniel T. Chang,Karyn A. Goodman,Siva P. Raman,Amy Hacker-Prietz,Mary E. Griffith,L. Colombo,Daniel A. Laheru,Albert C. Koong,Joseph M. Herman +9 more
Journal ArticleDOI
Pre-SBRT metabolic tumor volume and total lesion glycolysis to predict survival in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
Avani S. Dholakia,Muhammad Chaudhry,Jeffrey P. Leal,Daniel T. Chang,Siva P. Raman,Zheng Su,Amy Hacker-Prietz,Jonathan S. Pai,Mary E. Griffith,Richard L. Wahl,Erik Tryggestad,Timothy M. Pawlik,Daniel A. Laheru,Christopher L. Wolfgang,Albert C. Koong,Joseph M. Herman +15 more
TL;DR: This work analyzed the prognostic utility of PET for patients with locally advanced pancreatic cancer (LAPC) undergoing fractionated stereotactic body radiotherapy (SBRT) and found that liver measurability was assessed at a threshold based on the liver standard uptake value (SUV).